Abstract
A new series of 1-{(5-substituted-alkyl/aryl-1,3,4-oxadiazol-2-yl)methyl}-2-(piperidin-1-ylmethyl)-1Hbenzimidazoles (5a-5r) was synthesized and screened for their inhibitory activity against COX (1 and 2). In vivo antiinflammatory activity of potent compounds was done by carrageenan-induced rat paw edema model. In vitro anticancer activity of synthesized compounds was also performed at the National Cancer Institute (NCI) against NCI 60 cell lines panel. Out of the 18 compounds screened, 5h, 5i, 5j and 5l were found to be potent COX-2 inhibitors in the range of IC50 0.06-0.81 μM. In vivo anti-inflammatory screening results revealed that the compounds 5h and 5j manifested profound percent protection of 72.8 and 75.0%, respectively. Compound 5f exhibited moderate cytotoxicity with 58.79% growth inhibition against SNB-75 (CNS Cancer) cell lines and moderate activity against COX-2 (IC50 = 8.0 μM).
Keywords: Anti-inflammatory, anti-cancer, benzimidazoles, lipid peroxidation, piperidine, ulcerogenicity.
Graphical Abstract
Medicinal Chemistry
Title:Synthesis and Evaluation of Benzimidazole Derivatives as Selective COX-2 Inhibitors
Volume: 11 Issue: 2
Author(s): Ankita Rathore, Mujeeb-Ur-Rahman, Anees A. Siddiqui, Abuzer Ali and Mohammad Shahar Yar
Affiliation:
Keywords: Anti-inflammatory, anti-cancer, benzimidazoles, lipid peroxidation, piperidine, ulcerogenicity.
Abstract: A new series of 1-{(5-substituted-alkyl/aryl-1,3,4-oxadiazol-2-yl)methyl}-2-(piperidin-1-ylmethyl)-1Hbenzimidazoles (5a-5r) was synthesized and screened for their inhibitory activity against COX (1 and 2). In vivo antiinflammatory activity of potent compounds was done by carrageenan-induced rat paw edema model. In vitro anticancer activity of synthesized compounds was also performed at the National Cancer Institute (NCI) against NCI 60 cell lines panel. Out of the 18 compounds screened, 5h, 5i, 5j and 5l were found to be potent COX-2 inhibitors in the range of IC50 0.06-0.81 μM. In vivo anti-inflammatory screening results revealed that the compounds 5h and 5j manifested profound percent protection of 72.8 and 75.0%, respectively. Compound 5f exhibited moderate cytotoxicity with 58.79% growth inhibition against SNB-75 (CNS Cancer) cell lines and moderate activity against COX-2 (IC50 = 8.0 μM).
Export Options
About this article
Cite this article as:
Rathore Ankita, Mujeeb-Ur-Rahman , Siddiqui A. Anees, Ali Abuzer and Yar Shahar Mohammad, Synthesis and Evaluation of Benzimidazole Derivatives as Selective COX-2 Inhibitors, Medicinal Chemistry 2015; 11 (2) . https://dx.doi.org/10.2174/1573406410666140815121613
DOI https://dx.doi.org/10.2174/1573406410666140815121613 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Insights into the Mechanisms Underlying the Cholesterol- Lowering Effects of Phytosterols
Current Medicinal Chemistry Can Colorectal Cancer be Prevented or Treated by Oral Hormone Replacement Therapy?
Current Molecular Pharmacology New Approaches With Natural Product Drugs for Overcoming Multidrug Resistance in Cancer
Current Pharmaceutical Design Application of Nanotechnology in the Diagnosis and Therapy of Hepatocellular Carcinoma
Recent Patents on Anti-Cancer Drug Discovery FDG-PET/CT and SPECT/CT in Oncology
Current Medical Imaging Probiotics in the Prevention of Urogenital Tract Infections. Mechanisms Involved
Current Women`s Health Reviews The Molecular Basis of Th2 Development
Current Immunology Reviews (Discontinued) Ion-Pair Reversed-Phase Denaturing HPLC-Based Biotechnology as a Tool for Genetic Analysis
Current Pharmaceutical Analysis Molecular Determinants of Gastrointestinal and Liver Cancers: Role of Bile Acid Activated Nuclear Receptors
Current Topics in Medicinal Chemistry EGFR-Targeted Therapy in Malignant Glioma: Novel Aspects and Mechanisms of Drug Resistance
Current Molecular Pharmacology Evolution of the Strategies for Screening and Identifying Human Tumor Antigens
Current Protein & Peptide Science Editorial: Overview on microRNAs in Cancer Development and Virus Infection
MicroRNA Transductional and Transcriptional Targeting of Adenovirus for Clinical Applications
Current Gene Therapy Solvent-Drop Grinding Method: Efficient Synthesis, DPPH Radical Scavenging and Anti-diabetic Activities of Chalcones, bis-chalcones, Azolines, and bis-azolines
Current Organic Synthesis High Expression of miR-206 Predicts Adverse Outcomes: A Potential Therapeutic Target for Esophageal Cancer
Combinatorial Chemistry & High Throughput Screening The Use of Nitric Oxide Synthase Inhibitors in Inflammatory Diseases: A Novel Class of Anti-Inflammatory Agents
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents PRL-3, An Emerging Marker of Carcinogenesis, Is Strongly Associated with Poor Prognosis
Anti-Cancer Agents in Medicinal Chemistry Targeting Angiogenic Genes as a Therapeutic Approach for Hepatocellular Carcinoma
Current Gene Therapy CCK Receptors and Cancer
Current Topics in Medicinal Chemistry The Universal Nature, Unequal Distribution and Antioxidant Functions of Melatonin and Its Derivatives
Mini-Reviews in Medicinal Chemistry